Item 7.01 Regulation FD Disclosure.
On February 4, 2013, an alleged stockholder of Abiomed filed a derivative action
on behalf of Abiomed against Abiomed and each of its directors in the U.S.
District Court for the District of Massachusetts. The complaint alleges that the
directors breached their fiduciary duties to Abiomed and its stockholders in
connection with disclosures related to the U.S. Food and Drug Administration and
the marketing and labeling of our Impella 2.5 product and seeks damages in an
unspecified amount. Abiomed has reviewed the complaint and believes that the
allegations are without merit. Abiomed plans to vigorously defend itself against
the allegations. Abiomed's policy is not to discuss pending litigation.
Add
ABMD to Portfolio
Set Alert
Email to a
Friend